Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2012

View Archived Issues

Isis Innovation presents new dsNA molecules for Parkinson's disease

Del Mar Pharmaceuticals expands collaboration with Guangxi Wuzhou Pharmaceutical

Global phase III trial of ART-123 commences

AstraZeneca begins new global study of Faslodex

Astex Pharmaceuticals, CRT and Newcastle University form drug discovery alliance

Chinese researchers disclose novel Lp-PLA2 inhibitors

Astellas Pharma prepares new PDE10A inhibitors

New modulators of the expression of aquaporin-3 patented by Lipotec

Dainippon Sumitomo Pharma synthesizes novel nACh alpha7 receptor modulators

Researchers at Pathway Therapeutics disclose new PI3K inhibitors

Complix receives government grant for Alphabodies development

Takeda submits Japanese NDA for cetilistat

Astellas Pharma launches Quattrovac vaccine in Japan

Combination of BKM-120 and irinotecan evaluated in phase I trial

TransTech Pharma's TTP-488 slows cognitive decline in Alzheimer's disease

Preliminary phase II data presented for lubrinectedin in ovarian cancer

Cytokinetics begins phase IIb BENEFIT-ALS trial

Amgen offers overview of third quarter 2012 results

Novartis reports third quarter results for 2012

European Commission approves Cialis in new indication

FDA accepts two Latuda supplemental NDAs for review

Oral salmon calcitonin shows potential as antidiabetic therapy in vivo

GSK begins phase III program for mepolizumab in severe refractory asthma

Phase I IPH-2102 trial begins patient recruitment

NCI presents phase II data for a cervical cancer vaccine

Semaphorin-3A demonstrates osteoprotective qualities and therapeutic potential

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...